GEORGE L. ACKERMAN, M.D., F.A.C.P.; JAMES E. DOHERTY, M.D., F.A.C.P.; WILLIAM J. FLANIGAN, M.D.
The problems raised by reduced excretion of certain drugs or their metabolites make a knowledge of clinical pharmacology important to physicians treating patients with renal insufficiency. The growing availability of chronic dialysis therapy likewise necessitates a familiarity with the behavior of commonly prescribed drugs during dialytic procedures. Chronic renal failure is often accompanied by hypertensive heart disease, for which digitalis or one of its glycosides may be prescribed. Electrocardiographic changes resembling those encountered with digitalis intoxication may be seen during dialysis (1), and alertness to digitalis toxicity during dialysis has been advised by Lubash and associates (2).
We have studied
ACKERMAN GL, DOHERTY JE, FLANIGAN WJ. Peritoneal Dialysis and Hemodialysis of Tritiated Digoxin. Ann Intern Med. 1967;67:718–723. doi: 10.7326/0003-4819-67-4-718
Download citation file:
Published: Ann Intern Med. 1967;67(4):718-723.
Nephrology, Renal Replacement Therapy.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use